<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
close
 

From Organoids to In Vivo
with Confidence

PDX-derived organoids (PDXOs) combine the speed and flexibility of in vitro testing with the clinical relevance of PDX models, creating a highly translatable bridge for oncology drug development.

Explore Models

Translational Oncology Models

PDXOs fill the gap between fast but less predictive cancer cell lines and highly translatable but resource-intensive PDX trials. Leveraging Crown Bio’s expansive PDX library offers a wider array of cancer indications, genetic profiles, and pharmacology data than PDO collections alone.

  • Faster model generation at lower cost than de novo patient-derived models

  • Reduced animal use to align with the 3Rs principle

  • Flexible co-culture systems enabling addition of stromal or immune cells

  • Engineering capabilities for deeper mechanistic studies

  • Early adoption of clinically relevant models, moving seamlessly from in vitro to in vivo with matched, highly translatable systems

Webinar

Matched Model Pairs and Patient-Derived Xenografts and Organoids Biobanks

Study Options

organoid
Early Efficacy Screening

Transition seamlessly from organoid-based panel screening to matched PDX validation, maintaining the same tumor genotype and phenotype.

OrganoidXplore Screening
Laboratory Services
Biomarker Discovery and Validation
In vitro drug response with genomic/transcriptomic/proteomic data from matched PDXs for predictive biomarker development.
Laboratory Services
Mechanism of Action and Resistance Studies
Mechanism of Action and Resistance Studies

Use engineered PDXOs or co-cultures to explore drug mechanisms, resistance pathways, and immune interactions.

Target Resistance
Combination Therapy Development
Combination Therapy Development

Evaluate drug–drug or drug–radiation combinations in vitro, then validate in vivo with matched models.

Enroll Your Compounds
Translational In Vitro to In Vivo Workflows
Translational In Vitro to In Vivo Workflows

Move seamlessly from in vitro to in vivo models without changing the tumor’s genetic background, ensuring high translational confidence.

Watch How

Great Model Diversity

Crown Bioscience has developed more than 500 matched PDXO-PDX models across 22 cancer types, providing matched in vitro/in vivo systems for alignment across translational studies.

Visit Model Database

Cost-Effective and Ethical

Support the 3Rs of animal research by reducing reliance on animals while still leveraging patient-relevant tumor biology.

Read How

PDOs, PDXOs, PDOXs, or PDXs?

Select the best model to progress your patient-centric research.

Learn More

Frequently Asked Questions

How are PDXOs made?

PDXOs are derived from patient tumors expanded in PDX mouse models, maintaining key tumor characteristics.

How do PDXOs best complement PDX models?

PDXOs complement PDX studies by enabling faster, lower-cost in vitro screening before in vivo validation.

Can PDXOs be engineered?

Yes, they support genetic modifications and co-cultures with stromal or immune cells.

Ready To Start?

Learn how matched in vivo and in vitro models improve study efficiency and predictivity.

Contact Us